Cover Image
市場調查報告書

酪胺酸蛋白質激梅JAK1:開發中產品分析

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 367826
出版日期 內容資訊 英文 134 Pages
訂單完成後即時交付
價格
Back to Top
酪胺酸蛋白質激梅JAK1:開發中產品分析 Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2017
出版日期: 2017年05月31日 內容資訊: 英文 134 Pages
簡介

本報告提供以酪胺酸蛋白質激梅JAK1為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

酪胺酸蛋白質激梅JAK1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Advinus Therapeutics Ltd
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Chipscreen Biosciences Ltd
  • CJ HealthCare Corp
  • Eli Lilly and Company
  • Galapagos NV
  • Incyte Corp
  • 日本煙草產業
  • Jiangsu Hengrui Medicine Co Ltd
  • 日產化學工業
  • Pfizer Inc
  • Portola Pharmaceuticals Inc
  • Sareum Holdings Plc
  • Theravance Biopharma Inc
  • Vectura Group Plc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0799TDB

Summary

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 29 molecules are developed by Companies. The latest report Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 5, 4, 11 and 3 respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Central Nervous System, Hematological Disorders, Respiratory, Cardiovascular and Ophthalmology which include indications Rheumatoid Arthritis, Ulcerative Colitis, Atopic Dermatitis, Alopecia, Psoriasis, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma, Psoriatic Arthritis, Vitiligo, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Ankylosing Spondylitis (Bekhterev's Disease), B-Cell Non-Hodgkin Lymphoma, Crohn's Disease (Regional Enteritis), Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mantle Cell Lymphoma, Multiple Sclerosis, Myelodysplastic Syndrome, Myelofibrosis, Peripheral T-Cell Lymphomas (PTCL), Relapsed Multiple Myeloma, Waldenstrom Macroglobulinemia, Anaplastic Large Cell Lymphoma (ALCL), Asthma, Auto Inflammatory Disease, Autoimmune Disorders, Breast Cancer, Cancer Anorexia-Cachexia Syndrome, Chronic Asthma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Dermatitis, Dermatomyositis, Endometrial Cancer, Eosinophilia, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Giant Cell Arteritis, Hairy Cell Leukemia, Hypopharyngeal Cancer, Inflammatory Bowel Disease, Laryngeal Cancer, Lupus Erythematosus, Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Plaque Psoriasis (Psoriasis Vulgaris), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Respiratory Tract Inflammatory Disorders, Sicca Syndrome (Sjogren), Skin Inflammation, Systemic Lupus Erythematosus, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thalassemia, Thrombocythemia Myelofibrosis, Transitional Cell Cancer (Urothelial Cell Cancer) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Furthermore, this report also reviewsalso reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview
    • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Aclaris Therapeutics Inc
    • Advinus Therapeutics Ltd
    • Astellas Pharma Inc
    • AstraZeneca Plc
    • Chipscreen Biosciences Ltd
    • CJ HealthCare Corp
    • Eli Lilly and Company
    • Galapagos NV
    • Incyte Corp
    • Japan Tobacco Inc
    • Jiangsu Hengrui Medicine Co Ltd
    • Nissan Chemical Industries Ltd
    • Pfizer Inc
    • Portola Pharmaceuticals Inc
    • Sareum Holdings Plc
    • Theravance Biopharma Inc
    • Vectura Group Plc
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles
    • ABBV-599 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATI-50001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATI-50002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-0449 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-1480 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-4205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • baricitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cerdulatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-944X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCB-52793 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itacitinib adipate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JTE-052 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NIP-565 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • peficitinib hydrobromide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-04965842 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06700841 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PNQ-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PNQ-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ruxolitinib phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-20347 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SART-29 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHR-0302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Jak1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Janus Kinase for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TD-1473 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TD-3504 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • upadacitinib tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VR-588 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Discontinued Products
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Product Development Milestones
    • Featured News & Press Releases
      • May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association
      • May 15, 2017: Seven abstracts on filgotinib accepted by EULAR 2017
      • May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma
      • May 09, 2017: AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1-Selective Inhibitor, in Crohn's Disease
      • May 07, 2017: Galapagos presents three posters on filgotinib in Crohn's disease at DDW 2017
      • May 05, 2017: Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis
      • Apr 25, 2017: Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus
      • Apr 14, 2017: U.S. FDA Issues Complete Response Letter For Baricitinib
      • Apr 05, 2017: Galapagos doses first psoriatic arthritis patient with filgotinib
      • Apr 04, 2017: Aclaris Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Baricitnib for Hair Loss Disorders
      • Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studiesbwith filgotinib
      • Mar 10, 2017: New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease
      • Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization
      • Feb 15, 2017: Additional Results From Pivotal RA-BEAM Study Published In New England Journal Of Medicine Show Baricitinib-Treated Patients Demonstrated Sustained Improvement In Rheumatoid Arthritis Compared To Adalimumab And Placebo
      • Feb 13, 2017: European Commission Approves Once-Daily Olumiant Tablets For Treatment Of Adults With Moderate-To-Severe Active Rheumatoid Arthritis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by AbbVie Inc, H1 2017
  • Pipeline by Aclaris Therapeutics Inc, H1 2017
  • Pipeline by Advinus Therapeutics Ltd, H1 2017
  • Pipeline by Astellas Pharma Inc, H1 2017
  • Pipeline by AstraZeneca Plc, H1 2017
  • Pipeline by Chipscreen Biosciences Ltd, H1 2017
  • Pipeline by CJ HealthCare Corp, H1 2017
  • Pipeline by Eli Lilly and Company, H1 2017
  • Pipeline by Galapagos NV, H1 2017
  • Pipeline by Incyte Corp, H1 2017
  • Pipeline by Japan Tobacco Inc, H1 2017
  • Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Pipeline by Nissan Chemical Industries Ltd, H1 2017
  • Pipeline by Pfizer Inc, H1 2017
  • Pipeline by Portola Pharmaceuticals Inc, H1 2017
  • Pipeline by Sareum Holdings Plc, H1 2017
  • Pipeline by Theravance Biopharma Inc, H1 2017
  • Pipeline by Vectura Group Plc, H1 2017
  • Dormant Projects, H1 2017
  • Discontinued Products, H1 2017
  • Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
Back to Top